Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.46 |
| ▸ | ECE1 | P42892 | 1/20 | 0.44 |
| ▸ | GLP1R | P43220 | 1/20 | 0.44 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.44 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.44 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.44 |
| ▸ | TFPI | P10646 | 1/20 | 0.44 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30880884 | 0.91 | VIPR1 (0.46) | RXFP1ECE1GLP1RMUS81VIPR1 | |
| SCHEMBL31182628 | 0.87 | RXFP1 (0.54) | RXFP1ECE1GLP1RMUS81VIPR1 | |
| SCHEMBL30578726 | 0.86 | TFPI (0.49) | RXFP1TFPI | |
| SCHEMBL30859217 | 0.86 | TFPI (0.59) | RXFP1GLP1RVIPR1IL23RTFPI | |
| SCHEMBL29523429 | 0.86 | RXFP1 (0.52) | RXFP1ECE1GLP1RMUS81VIPR1 | |
| SCHEMBL30862319 | 0.85 | RXFP1 (0.57) | RXFP1ECE1GLP1RMUS81VIPR1 | |
| SCHEMBL30880897 | 0.84 | TFPI (0.49) | RXFP1ECE1GLP1RMUS81VIPR1 | |
| SCHEMBL30607321 | 0.83 | RXFP1 (0.60) | RXFP1VIPR1TFPIPTH1R | |
| SCHEMBL30536311 | 0.83 | VIPR1 (0.55) | RXFP1ECE1GLP1RMUS81VIPR1 | |
| SCHEMBL30437152 | 0.83 | RXFP1 (0.61) | RXFP1ECE1GLP1RMUS81VIPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| US-20240092878-A1 | AN ANTIBODY FRAGMENT BASED ANTIFUNGAL CONJUGATE SELECTIVELY TARGETING CANDIDA | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | SERPINH1, HM13, NGLY1 | RXFP1 3868/4885ECE1 468/4885GLP1R 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.